Biotech Selects Almac's Interactive Response Platform
A global biotech will be migrating to its newest generation Interactive Response Technology (IRT), platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.
Almac Clinical Technologies, part of the Almac Group, has announced that a global biotechnology company will be migrating to its newest generation Interactive Response Technology (IRT), IXRS® 3 platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.
Read the
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMGSeptember 15th 2025
Q&A: Strategies for Successful Global Clinical Trial DeliverySeptember 12th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
